reports
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company’s common stock with an exercise price of $6.79, the closing trading price of the Company’s common stock on the Nasdaq Global Market on...
Citizens Community Bancorp, Inc. Reports Fourth Quarter 2025 Earnings ...
Citizens Community Bancorp, Inc. Reports Fourth Quarter 2025 Earnings of $0.44 Per Share; Board Approves Moving to Quarterly Dividend at $0.105 per share EAU CLAIRE, Wis., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Citizens Community Bancorp, Inc. (the “Company”) (Nasdaq: CZWI), the parent company of Citizens Community Federal N.A. (the “Bank” or “CCFBank”), today reported earnings of $4.3 million and earnings per diluted share of $0.44 for the fourth quarter ended December 31, 2025, compared to $3.7 million and earnings per diluted share of $0.37 for the third quarter ended September 30, 2025, an...
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Ou...
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, Md., ...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company’s common stock with an exercise price of $6.76, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Boar...
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science and Technol...
- MarketLine Department
The Travelers Companies, Inc. - Mergers & Acquisitions (M&A), Partners...
Summary Marketline's The Travelers Companies, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by The Travelers Companies, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & A...
Moody's Ratings corrects its website display for certain notes issued ...
Moody's Ratings (Moody's) has corrected the display on its websites for Coty Inc.'s senior notes due in January 2029 (CUSIP 222070AG9) to reflect that these notes are senior secured. Additionally, the rating history has been revised to indicate that no action was taken on these notes on October 23, ...
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Tri...
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis 100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy Myositis seamless a...
- Jonathan Moreland
BLMN BLOOMIN' BRANDS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
DLY LYONDELLBASELL INDUSTRIES NV
KMPR KEMPER CORPORATION
GOOD GLADSTONE COMMERCIAL CORPORATION
FLDM FLUIDIGM
CROX CROCS INC.
ASA ASA
AROW ARROW FINANCIAL CORP.
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
REZI RESIDEO TECHNOLOGIES
FSK INC.
WU FS KKR CAPITAL CORP
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
AIMD.P AMCOR PLC
DKNG AIM4 VENTURES
OPEN DRAFTKINGS INC
ACVA OPENDOOR TECHNOLOGIES INC.
FRSH ACV AUCTIONS INC.
TRDA FRESHWORKS INC.
SG ENTRADA THERAPEUTICS INC
FRST SWEETGREEN INC
BLND PRIMIS FINANCIAL CORP
GTE ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
LAW GRAN TIERRA ENERGY INC.
MRAI CS DISCO INC
GF MARPAI
RMI INC.
THE NEW GERMANY FUND
INC.
RIVERNORTH OPPOR MUN INC FD INC
Kemper Corporation: 1 director
A director at Kemper Corporation bought 25,000 shares at 36.820USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results an...
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected by end of year Approximately $145.1 million cash, cash equivalents and restricted cash as of September 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phas...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to one employee an option to purchase an aggregate of 50,000 shares of the Company’s common stock with an exercise price of $8.85, the closing trading price of the Company’s common stock on the Nasdaq Global Market on ...
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairm...
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that Carsten Brunn, Ph.D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn, who currently serves as the Company’s President and Chief Executive Officer and as a member of the Board, will succeed Carrie S. Cox, who is stepping down t...
Citizens Community Bancorp, Inc. Reports Third Quarter 2025 Earnings o...
Citizens Community Bancorp, Inc. Reports Third Quarter 2025 Earnings of $0.37 Per Share; Redeems $15 Million of Subordinated Debt EAU CLAIRE, Wis., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Citizens Community Bancorp, Inc. (the “Company”) (Nasdaq: CZWI), the parent company of Citizens Community Federal N.A. (the “Bank” or “CCFBank”), today reported earnings of $3.7 million and earnings per diluted share of $0.37 for the third quarter ended September 30, 2025, compared to $3.3 million and earnings per diluted share of $0.33 for the second quarter ended June 30, 2025, and $3.3 million and $0.32 ear...
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On October 2, 2025, the Company issued to this employee an option to purchase an aggregate of 9,700 shares of the Company’s common stock with an exercise price of $10.34, the closing trading price of the Company’s common stock on the Nasdaq Global Market on ...
Moody's Ratings assigns Ba1 rating to Coty's new senior notes; outlook...
Moody's Ratings (Moody's) Moody's Ratings assigned a Ba1 rating to Coty Inc.'s ("Coty") new senior notes due 2031. Coty's subsidiaries HFC Prestige Products, Inc. (HFCPP), and HFC Prestige International U.S. LLC (HFCPI) are co-issuers of the notes. Proceeds are expected to be used to refinance exist...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
LKQ LKQ CORPORATION
ICUI ICU MEDICAL INC.
HBNC HORIZON BANCORP INC
EMN EASTMAN CHEMICAL COMPANY
D DOMINION ENERGY INC
CPRX CATALYST PHARMACEUTICALS
COTY COTY INC. CLASS A
ASYS AMTECH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
RLMD RELMADA THERAPEUTICS
QRHC QUEST RESOURCE HOLDING
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
NTLA INTELLIA THERAPEUTICS INC.
MX MAGNACHIP SEMICONDUCTOR CORP.
NWPP NEW PEOPLES BANKSHARES INC.
BHR BRAEMAR HOTELS & RESORTS
CCEL CRYO-CELL INTERNATIONAL
REZI RESIDEO TECHNOLOGIES
WU INC.
AVTR THE WESTERN UNION COMPANY
SELF AVANTOR
PGEN INC.
COO SELF STORAGE GROUP
REYN INC.
STTK PRECIGEN INC
ENOV THE COOPER COMPANIES INC.
BLIN REYNOLDS CONSUMER PRODUCTS INC.
EBC SHATTUCK LABS
NRGV ENOVIS CORPORATION
ONL BRIDGELINE DIGITAL INC
OBIO EASTERN BANKSHARES INC
ET ENERGY VAULT HOLDINGS INC
PROP ORION OFFICE REIT INC
BKKT ORCHESTRA BIOMED HOLDINGS INC
ISPO ENERGY TRANSFER LP
AFCG PRAIRIE OPERATING CO.
FG BAKKT HOLDINGS INC.
NIQ INSPIRATO INCORPORATED
STSS AFC GAMMA
FEAM INC.
SINT F AND G ANNUITIES AND LIFE
VWFB INC.
NIQ GLOBAL INTELLIGENCE PLC
SHARPS TECHNOLOGY INC.
5E ADVANCED MATERIALS INC.
SINTX TECHNOLOGIES INC.
VWF BANCORP
INC.
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.